Blood pressure variability (BPV) is considered nowadays a novel risk factor for cardiovascular disease. Clinical evidences
support that short-term and long-term BPV independently contribute to target organ damage, cardiovascular events and mortality in patients
with hypertension or diabetes. Attenuation of excessive fluctuations of systolic and diastolic BPV has been suggested as an additional
therapeutic target in cardiovascular prevention. A growing number of preclinical and clinical studies have focused in the assessment
of drug effects or other interventions on the different types of BPV and their contribution in the prevention of cardiovascular events.
Prospective clinical trials have shown that antihypertensive classes differ in their ability to control excessive BP fluctuations with an impact
in clinical outcomes. Current evidences suggest that calcium channel blockers are more effective than other blood pressure lowering
drugs for the reduction of short-term, mid-term and long-term BPV. In order to increase actual knowledge regarding the therapeutic significance
of BPV in cardiovascular disease, there is a need for additional clinical studies specifically designed for the study of the relevance
of short-term and long-term BPV control by antihypertensive drugs.
Keywords: Blood pressure variability, hypertension, diabetes, calcium channel blockers, visit-to-visit variability.
Rights & PermissionsPrintExport